Meijer Dennie, van Moorselaar R Jeroen A, Vis André N, Bijnsdorp Irene V
Department of Urology, Amsterdam University Medical Centers, Location VU Medical Center, 1081HV Amsterdam, The Netherlands.
Cancers (Basel). 2019 Jul 7;11(7):953. doi: 10.3390/cancers11070953.
: The role of statins in prostate cancer (PCa) remains unclear. Conflicting evidence has been found concerning risk reduction with the use of statins on biochemical recurrence (BCR). In this study, we evaluated whether statin use decreases the incidence of advanced PCa in males with elevated prostate-specific antigen (PSA; ≥4.0 ng/mL) levels and determined whether statin use reduces the risk of BCR after radical prostatectomy (RP). : Patients visiting the outpatient urology clinic of the VU Medical Center between 2006 and 2018 with elevated PSA were retrospectively analyzed. Biochemical recurrence after RP was defined as a PSA level of ≥0.2 ng/mL (measured twice). : A total of 1566 patients were included, of which 1122 (72%) were diagnosed with PCa. At the time of diagnosis, 252 patients (23%) used statins compared to 83 patients (19%) in the non-malignancy group ( = 0.10). No differences were found in the use of statins between the different risk groups. No correlation was found between the risk of BCR after RP and the use of statins in the total ( = 0.20), the intermediate-risk group ( = 0.63) or the high-risk group ( = 0.14). : The use of statins does not affect PCa development/progression in patients with elevated PSA levels, nor the development of BCR after RP.
他汀类药物在前列腺癌（PCa）中的作用仍不明确。关于使用他汀类药物降低生化复发（BCR）风险，已发现相互矛盾的证据。在本研究中，我们评估了使用他汀类药物是否会降低前列腺特异性抗原（PSA；≥4.0 ng/mL）水平升高的男性发生晚期PCa的发生率，并确定使用他汀类药物是否会降低根治性前列腺切除术（RP）后BCR的风险。：对2006年至2018年间到VU医学中心泌尿外科门诊就诊且PSA升高的患者进行回顾性分析。RP后的生化复发定义为PSA水平≥0.2 ng/mL（测量两次）。：共纳入1566例患者，其中1122例（72%）被诊断为PCa。在诊断时，252例患者（23%）使用他汀类药物，而非恶性肿瘤组为83例患者（19%）（P = 0.10）。不同风险组之间在他汀类药物使用方面未发现差异。在总人群（P = 0.20）、中风险组（P = 0.63）或高风险组（P = 0.14）中，RP后BCR风险与他汀类药物使用之间未发现相关性。：使用他汀类药物不会影响PSA水平升高患者的PCa发生/进展，也不会影响RP后BCR的发生。
